Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1 1

Status

Completed 6

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Stomach Neoplasms 13Carcinoma, Non-Small-Cell Lung 13Carcinoma, Hepatocellular 6Adenocarcinoma 6Neoplasms 5Lung Neoplasms 4Colorectal Neoplasms 4Colonic Neoplasms 4Breast Neoplasms 4Urethral Neoplasms 3Rectal Neoplasms 3Neoplasm Metastasis 3Liver Neoplasms 3Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Ureteral Neoplasms 2Solid Tumors 2Sarcoma 2Non-small Cell Lung Cancer Metastatic 2Malignant Solid Tumor 2Esophageal Neoplasms 2Carcinoma, Transitional Cell 2Biliary Tract Neoplasms 2Thymoma 1Solid Tumor 1Sarcoma, Synovial 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

Sorafenib 52pembrolizumab 26Nivolumab 20Bevacizumab 19Radiosurgery 17Doxorubicin 12atezolizumab 9Erlotinib Hydrochloride 9lenvatinib 8cabozantinib 7Magnetic Resonance Spectroscopy 7tremelimumab 6durvalumab 6Ramucirumab 6Radiofrequency Ablation 6Cisplatin 6Sunitinib 5tislelizumab 4regorafenib 4Oxaliplatin 4Leucovorin 4Ipilimumab 4Fluorouracil 4Everolimus 4Capecitabine 4nintedanib 3fluoromisonidazole 3carotuximab 3bavituximab 3Tomography, X-Ray Computed 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Has results × Carcinoma, Hepatocellular × Ramucirumab × Clear all
NCT02520141 2023-06-15

Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery

M.D. Anderson Cancer Center

Phase 2 Completed
61 enrolled 9 charts
Gastrointestinal

Gallbladder Neoplasms, Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT02435433 2023-01-20

REACH-2

Eli Lilly and Company

Phase 3 Completed
399 enrolled 22 charts 1 FDA
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT01246986 2021-01-12

A Study of LY2157299 in Participants With Hepatocellular Carcinoma

Eli Lilly and Company

Phase 2 Completed
204 enrolled 27 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT02069041 2018-11-21

A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer

Eli Lilly and Company

Phase 1 Completed
8 enrolled 16 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT01140347 2015-12-28

REACH

Eli Lilly and Company

Phase 3 Completed
565 enrolled 22 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT00627042 2014-10-08

Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy

Eli Lilly and Company

Phase 2 Completed
42 enrolled 19 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡